HLT-EMT39-05 · Lesson 7 · 28 clock hours · theory
Respiratory, Neurological, and Analgesic/Sedation Pharmacology
Objective. Students will explain the indications, contraindications, mechanism of action, and monitoring requirements for bronchodilators, neuromuscular blocking agents, analgesics, sedatives, and anticonvulsants used in prehospital care.
⚠ Pending professional review
This lesson, its worked examples and its practice questions has not yet been verified by a licensed clinician in the field or by a certification or approval body. It is a study draft and may contain errors. Do not use it to make decisions about any patient or medication. Always follow your instructor, your supervising professional, and current official references and regulations.
VoTechWorks program approval and accreditation are still in progress. Credentials are issued only by the certifying bodies named in each program, after their own exams.
Respiratory Pharmacology in Prehospital Care
Respiratory emergencies are among the most common calls EMS providers answer. Several drug classes are used to restore or protect the airway and improve ventilation.
Bronchodilators open constricted airways by relaxing bronchial smooth muscle. The most frequently used prehospital bronchodilators are short-acting beta-2 agonists such as albuterol (salbutamol). Albuterol acts on beta-2 adrenergic receptors in bronchial smooth muscle, causing relaxation and widening of the airway lumen. It is indicated for bronchospasm from acute asthma, COPD exacerbation, and anaphylaxis with bronchospasm. It is given by nebulization or metered-dose inhaler. Side effects include tachycardia, tremor, and hypokalemia with repeated doses. Ipratropium bromide is an anticholinergic bronchodilator often combined with albuterol; it blocks muscarinic receptors to reduce bronchoconstriction and secretions. Contraindications to ipratropium include hypersensitivity to atropine or peanuts (some formulations). Monitoring: continuous SpO2, respiratory rate, lung sounds before and after, and heart rate because beta-agonists can cause or worsen tachycardia.
For severe asthma unresponsive to inhaled therapy, magnesium sulfate (IV) acts as a smooth muscle relaxant and may be carried by ALS units. It must be given slowly; rapid infusion causes hypotension and flushing. Monitor blood pressure and deep tendon reflexes.
Epinephrine (IM or IV) is the cornerstone drug for anaphylaxis with bronchospasm and severe asthma as a secondary option; it stimulates both alpha and beta receptors to reverse bronchospasm and vasoconstriction.
Neuromuscular Blocking Agents and Rapid Sequence Intubation
Neuromuscular blocking agents (NMBAs) paralyze skeletal muscle by blocking acetylcholine at the neuromuscular junction. They do not provide sedation or analgesia; the patient remains conscious unless a sedative is given concurrently. This is the most critical safety point for NMBAs: never administer an NMBA without an appropriate sedative/analgesic agent.
NMBAs are divided into two classes:
- Depolarizing agents (e.g., succinylcholine) bind acetylcholine receptors and cause initial muscle fasciculations, then paralysis. Onset is very rapid (about 45–60 seconds). Duration is short (roughly 10–15 minutes) because it is hydrolyzed by plasma cholinesterase. Contraindications include known or suspected hyperkalemia, personal or family history of malignant hyperthermia, crush injuries older than 24–48 hours, burns, denervation injuries, and prolonged immobilization (risk of fatal hyperkalemia from receptor upregulation).
- Non-depolarizing agents (e.g., rocuronium, vecuronium) compete with acetylcholine without depolarizing the membrane. Onset is somewhat slower than succinylcholine (rocuronium at high doses approaches succinylcholine onset). Duration is longer. Sugammadex can reverse rocuronium rapidly where available.
Rapid sequence intubation (RSI) is the simultaneous administration of a sedative/induction agent and an NMBA to facilitate intubation while minimizing aspiration risk. RSI is a high-stakes intervention requiring advanced training and system medical-director authorization. Monitoring requirements: SpO2 before, during, and continuously after; ETCO2 waveform capnography after intubation to confirm and monitor tube placement; cardiac monitor; blood pressure.
Analgesics in EMS
Pain management is an essential and often undertreated part of prehospital care. The main categories are:
Opioid analgesics (e.g., morphine, fentanyl) bind mu-opioid receptors in the CNS to reduce pain perception. Fentanyl is lipid-soluble, fast-acting, and relatively hemodynamically stable, making it popular in EMS. Major risks: respiratory depression, hypotension, nausea. Naloxone reverses opioid effects and must be available any time an opioid is administered. Monitor respiratory rate, SpO2, blood pressure, and level of consciousness.
Ketamine is a dissociative anesthetic and analgesic that blocks NMDA receptors. At sub-dissociative (low) doses it provides analgesia without full dissociation. At higher doses it produces dissociative anesthesia for procedures or RSI induction. Benefits: generally maintains airway reflexes and hemodynamic stability, making it valuable for hypotensive trauma patients. Risks: laryngospasm (rare), emergence reactions, increased secretions. Monitoring: SpO2, level of consciousness using a sedation scale, and airway assessment.
Sedatives
Benzodiazepines (e.g., diazepam, midazolam, lorazepam) enhance GABA activity, producing sedation, anxiolysis, and anticonvulsant effects. Midazolam is short-acting and water-soluble, making it practical in the field. Risk: respiratory depression, especially combined with opioids. Monitor respiratory status and SpO2 closely.
Sedation scales (e.g., the Richmond Agitation-Sedation Scale, RAMSAY) provide objective reassessment of sedation depth after drug administration. A specific target score should be documented.
Anticonvulsants
Seizure management in prehospital care focuses on benzodiazepines as first-line agents. Midazolam, diazepam, and lorazepam all terminate active seizures by enhancing inhibitory GABA signaling. Intranasal or IM midazolam is effective when IV access is unavailable. Contraindications: benzodiazepines should be used cautiously with known respiratory compromise; have airway management equipment ready.
For refractory status epilepticus, some ALS systems carry levetiracetam or valproate for second-line treatment under medical direction.
Universal Monitoring and Safety Principles
- Always reassess vital signs, SpO2, and ETCO2 (where applicable) before and after every drug administration.
- Document drug name, dose, route, time, and patient response.
- Confirm allergies before administration.
- Know your system's approved drug list and scope of practice; do not administer any agent outside your medical-director protocol.
- Maintain reversal agents (naloxone, sugammadex if available) and airway equipment ready whenever administering sedatives or NMBAs.
Key terms10
Beta-2 agonistA drug class that selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle, causing bronchodilation; albuterol is the primary prehospital example.
Neuromuscular blocking agent (NMBA)A drug that interrupts transmission of nerve impulses at the neuromuscular junction, causing skeletal muscle paralysis without producing sedation or analgesia.
Rapid sequence intubation (RSI)An intubation technique in which a sedative/induction agent and an NMBA are given simultaneously to render the patient unconscious and paralyzed quickly, reducing aspiration risk.
Depolarizing NMBAA neuromuscular blocker (e.g., succinylcholine) that binds and activates acetylcholine receptors, causing brief fasciculations followed by paralysis; hydrolyzed rapidly by plasma cholinesterase.
Dissociative anesthesiaA state produced by agents such as ketamine in which the patient is analgesic and sedated but may appear awake; caused by NMDA receptor blockade.
ETCO2 (End-tidal carbon dioxide)The concentration of CO2 at the end of exhalation measured by capnography; used to confirm endotracheal tube placement and monitor ventilation adequacy.
Sedation scaleA standardized scoring tool (e.g., RAMSAY or RASS) that objectively measures depth of sedation, guiding drug titration in the field.
Status epilepticusA prolonged or repetitive seizure state without recovery of consciousness between episodes, representing a medical emergency requiring prompt pharmacological intervention.
NaloxoneAn opioid antagonist that competitively binds mu-opioid receptors to rapidly reverse respiratory depression and altered consciousness caused by opioid drugs.
Anticholinergic bronchodilatorA drug (e.g., ipratropium) that blocks muscarinic receptors in the airways, reducing bronchoconstriction and airway secretions; used as an adjunct to beta-2 agonists.
Worked examples4
1. A patient weighing 80 kg is in severe bronchospasm. The protocol calls for albuterol 2.5 mg via nebulizer. The albuterol solution on hand is 5 mg/mL. How many milliliters do you draw up?
- Identify the desired dose: 2.5 mg.
- Identify the available concentration: 5 mg per 1 mL.
- Apply the formula: Volume (mL) = Desired dose ÷ Concentration = 2.5 mg ÷ 5 mg/mL.
- Calculate: 2.5 ÷ 5 = 0.5 mL.
Answer: Draw up 0.5 mL of the albuterol 5 mg/mL solution to deliver a 2.5 mg dose.
2. Your protocol authorizes fentanyl 1 mcg/kg IV for a trauma patient weighing 70 kg. Fentanyl is available as 50 mcg/mL. What volume do you administer?
- Calculate the total dose: 1 mcg/kg × 70 kg = 70 mcg.
- Identify the concentration: 50 mcg per 1 mL.
- Apply the formula: Volume (mL) = Desired dose ÷ Concentration = 70 mcg ÷ 50 mcg/mL.
- Calculate: 70 ÷ 50 = 1.4 mL.
Answer: Administer 1.4 mL of the fentanyl 50 mcg/mL solution to deliver a 70 mcg dose.
3. A patient in active seizure weighs 60 kg. Your protocol orders midazolam 0.1 mg/kg IM. The midazolam vial is labeled 5 mg/mL. What volume do you inject?
- Calculate the total dose: 0.1 mg/kg × 60 kg = 6 mg.
- Identify the concentration: 5 mg per 1 mL.
- Apply the formula: Volume (mL) = 6 mg ÷ 5 mg/mL.
- Calculate: 6 ÷ 5 = 1.2 mL.
Answer: Inject 1.2 mL of midazolam 5 mg/mL IM to deliver the 6 mg dose.
4. For RSI, your protocol orders ketamine 1.5 mg/kg IV for a 90 kg patient. Ketamine is available as 10 mg/mL. What volume do you administer?
- Calculate the total dose: 1.5 mg/kg × 90 kg = 135 mg.
- Identify the concentration: 10 mg per 1 mL.
- Apply the formula: Volume (mL) = 135 mg ÷ 10 mg/mL.
- Calculate: 135 ÷ 10 = 13.5 mL.
Answer: Administer 13.5 mL of ketamine 10 mg/mL IV to deliver the 135 mg induction dose.
The math in this lesson1
Learners divide a 2.5 mg albuterol dose by 5 mg/mL to draw up 0.5 mL.
7.RP.2
In class: Drug card project continued: students complete standardized reference cards for respiratory, neurological, analgesic, and sedation agents, noting specific monitoring requirements such as SpO2, ETCO2, and sedation scale. · Case-study analysis: students read three complex patient cases (severe asthma, seizure, traumatic pain management) and write a structured pharmacological treatment plan with dose calculation, route, and monitoring plan for each. · Small-group debate: should EMS systems carry neuromuscular blocking agents for RSI? Groups research position using the textbook and assigned reading, then present arguments with pharmacological evidence.
Materials: EMS pharmacology textbook, completed drug card templates, case-study handouts, assigned reading on RSI evidence, whiteboard
Check: Written unit exam (30 multiple-choice questions) covering respiratory, neurological, and analgesic/sedation pharmacology; pass mark 80%. Failed exam requires remediation and alternate-form retest.
Practice check8
Answer each question, then check it. Nothing is recorded; this is your own practice.
Record this lesson on my transcript. Sign in with your key and enrollment email to record lessons (enroll free if you have no key). This page stays open to read and practise.